4-[5-(4-(4-methylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[5-(4-(4-methylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
• 英文别名: 4-[5-(4'-methyl[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide；4-[5-(4'-methyl[1,1'-biphenyl]4-yl)-3-(trifluoromethyl)-1H-1-yl]benzenesulfonamide；4-[5-[4-(4-Methylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
• 化学式: C₂₃H₁₈F₃N₃O₂S
• 分子量: 457.476
• InChiKey: AYAWQPVJTYWMSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-乙酰基-4'-甲基联苯 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.0h， 生成 4-[5-(4-(4-methylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018

文献信息

• Compounds and methods for inducing apoptosis in proliferating cells
  申请人：——

  公开号：US20030236294A1

  公开（公告）日：2003-12-25

  Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-smalll cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.

  用于诱导增殖细胞凋亡的化合物，特别是癌细胞，包括但不限于前列腺癌、白血病、非小细胞肺癌、结肠癌、中枢神经系统癌、黑色素瘤、卵巢癌、肾癌、膀胱癌、淋巴瘤和乳腺癌。这些化合物在治疗雄激素非依赖性癌症特别有效，包括激素难治性前列腺癌。还提供了使用本发明化合物治疗患有癌症的受试者的方法。此外，还提供了使用本发明化合物治疗、抑制或延迟受试者癌症发生的方法。此外，还提供了使用本发明化合物诱导快速增殖细胞凋亡的方法，特别是虽然不一定是癌细胞。
• COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS
  申请人：THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION

  公开号：EP1499597A2

  公开（公告）日：2005-01-26
• EP1499597A4
  申请人：——

  公开号：EP1499597A4

  公开（公告）日：2006-01-25
• US7026346B2
  申请人：——

  公开号：US7026346B2

  公开（公告）日：2006-04-11
• [EN] COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS<br/>[FR] COMPOSES ET METHODES PERMETTANT D'INDUIRE L'APOPTOSE CHEZ DES CELLULES DE PROLIFERATION
  申请人：UNIV OHIO STATE RES FOUND

  公开号：WO2003086287A2

  公开（公告）日：2003-10-23

  Compounds useful for inducing apoptosis in proliferate cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.